A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
Cancer|Neoplasms|Metastatic Cancer|Triple Negative Breast Cancer|Gastric Cancer|Cervical Cancer|Ovarian Cancer|Hepatocellular Carcinoma|Squamous Cell Carcinoma of Head and Neck|Urothelial Carcinoma|Urothelial Neoplasm|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Locally Advanced Solid Tumor|Locally Advanced Malignant Neoplasm|Squamous Cell Carcinoma|Sarcoma|Merkel Cell Carcinoma|Bladder Cancer
DRUG: OC-001|DRUG: Drug: OC-001 in Combination with Avelumab
Number of participants with a Dose Limiting Toxicity (DLT) in Phase 1b, A Dose-Limiting Toxicity (DLT) is defined as an Adverse Event (AE) that is likely related to the study medication or combination, and fulfills any one of the criteria identified in the Common Terminology Criteria for Adverse Events (CTCAE, Version 5), Baseline through Cycle 1 (Day 28)|Number of participants with any Serious Adverse Event or Treatment-Emergent Adverse Event in Phase 2a, Number of participants with any Serious Adverse Event or Treatment-Emergent Adverse Event in Phase 2a, Baseline up to two years
Area Under the OC-001 Plasma Concentration Time Curve (AUC) in Phase 1b, After single and multiple dose administration, Baseline through 12 weeks|Maximum Observed OC-001 Concentration (Cmax) in Phase 1b, After single and multiple dose administration, Baseline through 12 weeks|Time to reach OC-001 Cmax (Tmax) in Phase 1b, Time of maximum concentration observed, Baseline through 12 weeks|Minimum Observed OC-001 Concentration (Cmin) in Phase 1b, After single and multiple dose administration, Baseline through 12 weeks|Overall Response Rate (ORR) in Phase 2a, In combination with Avelumab, Baseline up to two years|Progression Free Survival (PFS) in Phase 2a, In combination with Avelumab, Baseline up to two years|Duration of Response (DOR) in Phase 2a, In combination with Avelumab, Baseline up to two years|Time to Response (TTR) in Phase 2a, In combination with Avelumab, Baseline up to two years|Disease Control Rate (DCR) in Phase 2a, In combination with Avelumab, Baseline up to two years|Overall Survival (OS) in Phase 2a, In combination with Avelumab, Baseline up to two years|One-Year Survival Rate in Phase 2a, In combination with Avelumab, Baseline up to two years|Maximum Observed OC-001 Concentration (Cmax) in Phase 2a, In combination with Avelumab, Baseline through 12 weeks|Minimum Observed OC-001 Concentration (Cmin) in Phase 2a, In combination with Avelumab, Baseline through 12 weeks|Trough drug concentration of OC-001 (Ctrough) in Phase 2a, In combination with Avelumab, Baseline through 12 weeks
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types